Patients with metastatic APF lymph nodes (n=4) | Patients with non-metastatic APF lymph nodes (n=45) | Patients without APF lymph nodes (n=233) | |
---|---|---|---|
Mean age at surgery (range) | 63.8 (62–65) | 63 (44–73) | 64 (43–76) |
Preop PSA, ng/mL (%) | |||
0–3.9 | 1 (25.0) | 2 (4.4) | 9 (3.9) |
4–10 | 1 (25.0) | 21 (46.7) | 134 (57.5) |
>10 | 2 (50.0) | 22 (48.9) | 90 (38.6) |
Preop histology (%) | |||
3+3=6 | 1 (25.0) | 11 (24.4) | 89 (38.2) |
3+4=7 | 1 (25.0) | 24 (53.3) | 111 (47.6) |
4+3=7 | 1 (25.0) | 8 (17.8) | 30 (12.9) |
≥8 | 1 (25.0) | 2 (4.4) | 3 (1.3) |
Pathological T stage (%) | |||
pT2 | 1 (25.0) | 27 (60.0) | 145 (62.2) |
pT3 | 3 (75.0) | 18 (40.0) | 88 (37.8) |
Mean total tumour volume, mL (range) | 8.68 (2.1–12.3) | 3.7 (0.1–15) | 3.85 (0.01–38) |
Anterior primary tumour (%) | 4 (100) | 8 (17.7) | 54 (23.2) |
Vascular invasion (%) | 1 (25.0) | 4 (8.9) | 14 (6.0) |
Seminal vesicle invasion, n (%) | 1 (25.0) | 5 (11.1) | 16 (6.9) |
Pathological Gleason score (%) | |||
No tumour | – | – | 1 (0.4) |
3+3=6 | – | 11 (24.4) | 51 (21.9) |
3+4=7 | – | 20 (44.4) | 128 (54.9) |
4+3=7 | 1 (25.0) | 13 (28.9) | 40 (17.2) |
>8 | 3 (75.0) | 1 (2.2) | 13 (5.6) |
APF, anterior prostatic fat; PSA, prostrate specific antigen.